| P2093 | author name string | Klaus Podar | |
| | Sonia Vallet | |
| P2860 | cites work | Multiple Myeloma | Q56453538 |
| | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma | Q57903998 |
| | Bortezomib for AL amyloidosis: moving forward | Q57904537 |
| | Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M | Q58051897 |
| | Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma | Q58415969 |
| | A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function | Q24297354 |
| | Identification of a primary target of thalidomide teratogenicity | Q24302178 |
| | DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival | Q24311448 |
| | Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide | Q24614147 |
| | RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis | Q24626854 |
| | Initial genome sequencing and analysis of multiple myeloma | Q24629117 |
| | A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide | Q26865089 |
| | Lysine acetylation targets protein complexes and co-regulates major cellular functions | Q27860589 |
| | Proteasome inhibitors disrupt the unfolded protein response in myeloma cells | Q28155919 |
| | 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes | Q28213670 |
| | The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 |
| | BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 |
| | Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function | Q28383385 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Cdc42 regulates neutrophil migration via crosstalk between WASp, CD11b, and microtubules | Q30527782 |
| | In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model | Q33362103 |
| | Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma | Q33383550 |
| | A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies | Q33387006 |
| | Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study | Q33394281 |
| | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study | Q33394981 |
| | Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma | Q33399706 |
| | Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma | Q33401018 |
| | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study | Q33401457 |
| | A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma | Q33401596 |
| | A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma | Q33402144 |
| | A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma | Q33402536 |
| | A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma | Q33402671 |
| | The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance | Q40569001 |
| | IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells | Q40616669 |
| | Induction of Osteoclast Differentiation by Runx2 through Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and Osteoprotegerin Regulation and Partial Rescue of Osteoclastogenesis in Runx2–/– Mice by RANKL Transgene | Q40655044 |
| | Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma | Q40702649 |
| | A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. | Q42728666 |
| | PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo | Q42821645 |
| | Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). | Q42965343 |
| | Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). | Q43250016 |
| | Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | Q43648034 |
| | Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial | Q43700291 |
| | Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. | Q43711552 |
| | Multiple myeloma, version 1.2013. | Q44011192 |
| | Antimyeloma efficacy of thalidomide in the SCID-hu model | Q44189788 |
| | Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. | Q44348524 |
| | Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial | Q44442859 |
| | NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma | Q44484456 |
| | Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib | Q44937333 |
| | High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. | Q45910770 |
| | High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. | Q46025960 |
| | Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma | Q46505738 |
| | Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma | Q46584146 |
| | Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma | Q46735730 |
| | Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells | Q46882677 |
| | Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion | Q47371978 |
| | A gene expression signature for high-risk multiple myeloma. | Q47590597 |
| | Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. | Q51401479 |
| | Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. | Q51833653 |
| | Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. | Q52569752 |
| | Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. | Q53127020 |
| | A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. | Q53246749 |
| | Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. | Q54614177 |
| | Bacterial sepsis and GI tract GVHD: more commensal than you think | Q55014775 |
| | Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma | Q33648344 |
| | Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma | Q33732491 |
| | Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease | Q33740176 |
| | A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma | Q33829132 |
| | Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma | Q33854012 |
| | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 |
| | Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib | Q34008578 |
| | An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma | Q34008600 |
| | A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma | Q34134986 |
| | Minor clone provides a reservoir for relapse in multiple myeloma | Q34147170 |
| | Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. | Q34156748 |
| | Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. | Q34210005 |
| | Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy | Q34263870 |
| | The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways | Q34368551 |
| | Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma | Q34369823 |
| | A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib | Q34467271 |
| | The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. | Q34568855 |
| | The 5TMM series: a useful in vivo mouse model of human multiple myeloma | Q34580353 |
| | A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma | Q34634446 |
| | Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma | Q34635516 |
| | Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). | Q34974362 |
| | RANK ligand and osteoprotegerin in myeloma bone disease. | Q34992857 |
| | In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells | Q35167162 |
| | Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone | Q35485758 |
| | CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma | Q35610286 |
| | Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. | Q35643032 |
| | Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications | Q35734509 |
| | Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease | Q35794132 |
| | Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment | Q35802226 |
| | The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis | Q35830099 |
| | The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications | Q35912178 |
| | Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma | Q35915726 |
| | A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. | Q35984702 |
| | MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. | Q36141697 |
| | Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides | Q36141838 |
| | Clonal competition with alternating dominance in multiple myeloma. | Q36141846 |
| | Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease | Q36169814 |
| | Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma | Q36206430 |
| | Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells | Q36286862 |
| | Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. | Q36333522 |
| | A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance | Q36338365 |
| | Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma | Q36384889 |
| | Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma | Q36407209 |
| | Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 |
| | Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. | Q36498366 |
| | Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics | Q36721503 |
| | Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu | Q36835070 |
| | Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. | Q36883307 |
| | Treatment strategies for bone disease | Q36902828 |
| | CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells | Q37176556 |
| | Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. | Q37207049 |
| | Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case | Q37246775 |
| | Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma | Q37357340 |
| | Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma | Q37379984 |
| | Alternative splicing and biological heterogeneity in prostate cancer | Q37573399 |
| | Novel bone-targeted strategies in oncology | Q37774141 |
| | Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. | Q37835572 |
| | New insights into therapeutic targets in myeloma | Q37967269 |
| | Have drug combinations supplanted stem cell transplantation in myeloma? | Q38021459 |
| | A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma | Q38051475 |
| | Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events | Q39583670 |
| | Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab | Q39627268 |
| | Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. | Q39718152 |
| | Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome | Q39813739 |
| | Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 |
| | The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo | Q39840677 |
| | Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer | Q40016892 |
| | CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib | Q40040623 |
| | Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model | Q40211681 |
| | IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma | Q40425654 |
| | Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors | Q40520603 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S35-53 | |
| P577 | publication date | 2013-06-17 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | New insights, recent advances, and current challenges in the biological treatment of multiple myeloma | |
| P478 | volume | 13 Suppl 1 | |